Skip to main content
Article thumbnail
Location of Repository

Characterization of a major neutralizing epitope on the yellow fever virus envelope protein using human recombinant monoclonal antibody fragments generated by phage display

By Stephane Daffis


Yellow fever virus (YFV) is a mosquito-transmitted, enveloped, positive stranded RNA virus belonging to the genus flavivirus, which causes hemorrhagic fever in humans in Africa and South America. The YFV is responsible for 200 000 clinical infections per year including 40 000 deaths. Despite the presence of a highly effective YF vaccine called 17D vaccine, this disease is now strongly re-emerging and has to be considered as a public health problem. The present live attenuated 17D vaccine has two major drawbacks: 1) the ancient production method by inoculating viable embryonated eggs which limits the vaccine production capacity and, therefore, impairs attempts to control the disease and may contribute to vaccine supply shortage. 2) this vaccine is a non clonal vaccine which is constituted of heterogenous virion sub-populations. Furthermore, recent reports of several cases of viscerotropic and neurotropic disease associated with 17D vaccination have raised the obvious question of vaccine safety. Taken together, these data show that it appears essential to design a new clonal vaccine which could be based on infectious cDNA clone and produced in animal cell culture. For this purpose, the knowledge of YFV neutralizing epitopes is essential. Because YFV immunity is mainly antibody-mediated, we wanted to isolate human neutralizing antibodies specific for YFV and use them as a tool to characterize the neutralizing epitopes of YFV. The phage display technology provides one of the most convenient systems to isolate such neutralizing recombinant antibody fragments. We generated YF patient-derived antibody phage libraries which were screened against purified virions of the YFV-204-WHO vaccine strain. This step led to the isolation of several single-chain antibody fragments (scFv) which recognized conformational and pH sensitive epitopes in the envelope E protein. Three genetically closely-related and competing scFvs were found to be able to neutralize in vitro the 17D vaccine strain and five wild-type African strains of YFV. To map their epitopes, neutralization escape variants of the YFV-17D-204-WHO were generated using one high-affinity scFv (scFv-7A). Amino acids (aa) E-153, E-154 and E-155 in domain I and aa E-71 in domain II of the E protein were shown to be the critical components of one complex neutralizing epitope. These aa do not form a contiguous epitope on the monomeric E protein, but are in close vicinity in the dimeric form the E protein is predicted to adopt, based on the crystal structures of related flaviviruses. The neutralizing epitope is thus predicted to be formed by contribution of aa from domain I and II of opposing E monomers. The nature of this epitope was supported by the analysis of one wild-type YFV strain (Senegal 90) which is naturally resistant to neutralization by scFv-7A. Microneutralization assays using sera from YFV-infected patients and 17D-immunized travelers confirm the importance of E-71 in YFV neutralization but also showed that those escape variants, originally present in the vaccine lot, do not carry a risk of neutralization escape in persons who are immunized with the 17D vaccine. The potential neutralization mechanism by which these scFvs act, particularly by preventing the fusion process, and their potential use as a therapeutical tool are discussed. The structural complexity of the epitope identified in this work has implications for understanding the mechanism of antibody-mediated neutralization of YFV and these data may be useful for the design of a new recombinant yellow fever vaccine based on a cDNA-derived infectious clone

Topics: Impfstoff ; Gelbfieber ; Yellow fever virus ; Phagen-Display-Bibliothek ; Virologie ; Phage display ; Flaviviren ; Gelbfiebervirus ; Neutralizing epitopes ; Antibody fragments ; Medical sciences, Medicine, Impfstoff -- Gelbfieber -- Yellow fever virus -- Phagen-Display-Bibliothek -- Virologie -- Phage display -- Flaviviren -- Gelbfiebervirus -- Medizin, Gesundheit -- Neutralizing epitopes -- Antibody fragments, ddc:610
Publisher: Philipps-Universität Marburg, Medizin
Year: 2006
OAI identifier:

Suggested articles


  1. 09/2000-06/2001 Praktikum im Labor „Oncogenesis, Differenciation and Signal Transduction“,
  2. (2002). 12/2005 Doktorarbeit am Institut für Virologie, Marburg, Deutschland. Thema:“Characterization of a major neutralizing epitope on the yellow fever virus envelope protein using human recombinant monoclonal antibody fragments generated by phage display.”
  3. (1994). a D155G mutation together with a G303K mutation in a 17D virus variant was isolated from a human case of vaccine-associated encephalitisV-DISCUSSION 103
  4. (2004). A death associated with yellow fever vaccination reported in
  5. (2003). A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizingantibody combining sites. J-Virol. doi
  6. (2001). A model for neutralization of viruses based on antibody coating of the virion surface. doi
  7. (2000). A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J-Med-Virol. doi
  8. (1986). A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature. doi
  9. (2003). A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J-Gen-Virol. doi
  10. (2005). A structural perspective of the flavivirus life cycle. Nat-Rev-Microbiol. doi
  11. (2004). Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J-Infect-Dis. doi
  12. (2004). Activation of the Cytokine Network and Unfavourable Outcome in Patients with Yellow Fever ter doi
  13. (2001). Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J-MedVirol. doi
  14. (1999). Analysis of the steps involved in Dengue virus entry into host cells. Virology. doi
  15. (1995). Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J-Med-Virol. doi
  16. (2001). Antibody Engineering. doi
  17. (2003). Antigenic structure of flavivirus proteins. Adv-Virus-Res. doi
  18. (1989). Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J-Virol. doi
  19. (1997). Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology. doi
  20. (2001). Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein. J-Virol. doi
  21. (2000). Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J-Virol. doi
  22. (1999). Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. J-Virol.
  23. (2001). Biophysical characterization and vector-specific antagonist activity of domainVI-LITERATURE 116 III of the tick-borne flavivirus envelope protein. J-Virol. doi
  24. (2003). Broadly cross-reactive HIV neutralizing human monoclonalVI-LITERATURE 130 antibody Fab selected by sequential antigen panning of a phage display library. J-Immunol-Methods. doi
  25. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. ProcNatl-Acad-Sci-U-S-A. doi
  26. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J-Mol-Biol.
  27. (2003). Cellular and Molecular Immunology:
  28. (1997). Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology. doi
  29. (2004). Characterization of a membrane-associated trimeric low-pH-induced Form of the class II viral fusion protein E from tick-borne encephalitis virus and its crystallization. JVirol. doi
  30. (1989). Characterization of antigenic variants of tick-borne encephalitis virus selected with neutralizing monoclonal antibodies. J-Gen-Virol. doi
  31. (1982). Characterization of blood mononuclear cells reacting with K 562 cells after yellow fever vaccination. Cell-Immunol. doi
  32. (1996). Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody. Virus-Res. doi
  33. (2005). Characterization of neutralizing antibodies to West Nile virus. Virology. doi
  34. (1988). Chimeric single-stranded DNA phage-plasmid cloning vectors. Biotechnology. doi
  35. (1965). Circulating Virus, Interferon and Antibody After Vaccination With the 17-D Strain of Yellow-Fever Virus. N-Engl-J-Med. doi
  36. (1989). Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc-NatlAcad-Sci-U-S-A. doi
  37. (1986). Comparison of neurovirulence of different strains of yellow fever virus in mice. J-Gen-Virol. doi
  38. (1987). Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc-Natl-Acad-Sci-U-S-A. doi
  39. (1987). Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. J-Mol-Biol. doi
  40. (2003). Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO-Rep. doi
  41. (2005). Departments of Medicine, Molecular Microbiology, Pathology and Immunology, doi
  42. (2005). described that a neutralizing Fab fragment specific for domain III was able to neutralize the WNV not by blocking virus attachment to its target cell as expected, but at a step after viral attachment (Nybakken
  43. (1983). Detection des IgM antiamariles devant une hepatite icterigene contractee en milieu tropical. Presse-Med.
  44. (2005). Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. NatMed. doi
  45. (1998). Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J-Med-Virol. doi
  46. (2005). Differences in the postfusion conformations of full-length and truncated class II fusion protein E of tick-borne encephalitis virus. J-Virol. doi
  47. (1978). E-mail: Date and place of birth: 12
  48. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. JVirol.
  49. (2000). Effect of tunicamycin on expression of epitopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells. Acta-Virol.
  50. (2000). Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries. Clin-Exp-Immunol. doi
  51. (1986). Emergence endemique de la fievre jaune en Cote d'Ivoire: place de la detection des IgM antiamariles dans la strategie de surveillance. BullWorld-Health-Organ.
  52. (2005). Engineered antibody fragments and the rise of single domains. Nat-Biotechnol. doi
  53. (2003). Epidemiology and ecology of yellow fever virus. Adv-Virus-Res. doi
  54. (2004). Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J-Virol. doi
  55. (2001). Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology. doi
  56. (1999). Facing up to re-emergence of urban yellow fever. Lancet. doi
  57. (2001). Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. doi
  58. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. doi
  59. (1991). Filamentous phage assembly. Mol-Microbiol. doi
  60. (2001). Flaviviridae: the viruses and their replication.
  61. (2003). Flavivirus structure and membrane fusion. Adv-VirusRes. doi
  62. (2003). Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J-MedVirol. doi
  63. (2004). Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region. J-Virol. doi
  64. (2004). Gesellschaft für Virologie,
  65. (2005). Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J-Virol. doi
  66. (2002). Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology. doi
  67. (2002). Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral-Res. doi
  68. (2001). Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. doi
  69. (1992). Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology. doi
  70. (2002). Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. doi
  71. (2002). Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein doi
  72. (2004). Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. doi
  73. (1992). Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc-Natl-Acad-Sci-U-S-A. doi
  74. (1999). Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. J-Gen-Virol.
  75. (2003). Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology. doi
  76. (1991). Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites.
  77. (2001). Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. J-Virol. doi
  78. (2002). Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. doi
  79. (1990). Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. J-Gen-Virol. doi
  80. (2002). Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J-Virol. doi
  81. INCODEV annual meeting, 2004, Paris, France.VII-ANNEXES 137 Posters. Mapping of neutralizing epitopes on domain I and II of the yellow fever virus envelope glycoprotein with human recombinant antibodies generated through phage display.
  82. (1996). Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitopeblocked panning. J-Immunol.
  83. (2004). Isolation of human monoclonal antibodies that neutralize human rotavirus. J-Virol. doi
  84. (1981). Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J-Gen-Virol. doi
  85. (1986). Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J-Gen-Virol. doi
  86. (2004). Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J-Virol. doi
  87. (1987). Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain). Virology. doi
  88. (2001). Locus of a virus neutralization epitope on the Japanese encephalitis virus envelope protein determined by use of long PCR-based region-specific random mutagenesis. Virology. doi
  89. (2001). Mechanisms of virus neutralization by antibody. Curr-Top-Microbiol-Immunol. doi
  90. (1999). Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology. doi
  91. (2003). Molecular biology of flaviviruses. Adv-Virus-Res. doi
  92. (2003). Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J-Virol. doi
  93. (2004). Molecular determinants of virulence of West Nile virus in North America. Arch-Virol-Suppl. doi
  94. (2001). Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J-Virol. doi
  95. (1996). Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Eur-J-Immunol. doi
  96. (1999). Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology. doi
  97. (1998). Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology. doi
  98. (1996). Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology. doi
  99. (2001). Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. doi
  100. (1978). Name, Vorname: DAFFIS, Stephane Geburtsort/Datum 12. März
  101. (1986). Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J-GenVirol. doi
  102. (1995). Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J-Gen-Virol doi
  103. (2004). Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J-Gen-Virol. doi
  104. (2002). Neutralizing human Fab fragments against measles virus recovered by phage display. J-Virol. doi
  105. (1995). Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J-Immunol.
  106. (1991). Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology. doi
  107. (1985). Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. doi
  108. (1995). Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J-Virol. doi
  109. (1991). Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur-J-Immunol. doi
  110. (2002). Overview of antibody phage-display technology and its applications. Methods-Mol-Biol. doi
  111. (2003). Pathogenesis and pathophysiology of yellow fever. Adv-Virus-Res. doi
  112. (2002). Phage display technology: clinical applications and recent innovations. Clin-Biochem. doi
  113. (1999). Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J-Nucl-Med. doi
  114. (1995). Phenotypic analysis of yellow fever virus derived from complementary DNA. Am-J-Trop-Med-Hyg.
  115. (1999). Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virology. doi
  116. (1986). Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J-Virol.
  117. (1990). Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J-Gen-Virol. doi
  118. (2005). Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South-Med-J. doi
  119. (1999). Recombinant human monoclonal antibodies to Ebola virus. J-Infect-Dis. doi
  120. (1994). Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. doi
  121. (1952). Research on dengue during World War II. Am-J-Trop-Med-Hyg.
  122. (2004). Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol-Infect. doi
  123. (2003). Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. Virology. doi
  124. (2001). Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus. J-Virol. doi
  125. (2001). Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin-Exp-Immunol. doi
  126. (2001). Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. doi
  127. (2001). Shortage of vaccines during a yellow fever outbreak in Guinea. Lancet. doi
  128. (1998). Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J-Virol.
  129. (1993). Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J-Gen-Virol. doi
  130. (2005). Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. doi
  131. (1996). Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J-Virol.
  132. (2004). Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO-J. doi
  133. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. doi
  134. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature. doi
  135. (2000). Studies of deglycosylated epitopes of JEV have shown a loss of interaction with well-characterized JEV-specific monoclonal antibodies (Lad et al.,
  136. (1991). T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus. J-Virol.
  137. (2003). Taxonomy of the virus family Flaviviridae. AdvVirus-Res. doi
  138. (1997). the adaptation of Dengue virus in mosquito cells result in the loss of the glycosylation site at position E-153 (Lee et al.,
  139. (2001). The biopanning procedure was mainly performed as described in the laboratory manual “Antibody engineering” (Kontermann and Duebel,
  140. (2004). The entry machinery of flaviviruses. doi
  141. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. doi
  142. (1993). The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology. doi
  143. (2005). The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur-J-Immunol. doi
  144. (1991). The primers used in this study are those described by
  145. (1999). The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J-Virol.
  146. (1996). Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Virology. doi
  147. (1989). Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.
  148. (1999). Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology. doi
  149. (1992). Variation in the biological function of envelope protein epitopes of yellow fever vaccine viruses detected with monoclonal antibodies. Biologicals. doi
  150. (2004). Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J-Gen-Virol. doi
  151. (2003). Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J-Virol. doi
  152. (2003). Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat-Struct-Biol. doi
  153. (2006). Vorliegende Arbeit wurde in folgenden Publikationsorganen veröffentlicht:
  154. (1995). When it's better to lie low. doi
  155. (2005). Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. doi
  156. (2004). Yellow Fever Vaccine. doi
  157. (1997). Yellow fever vaccines. Biologicals. doi
  158. (2001). Yellow fever virus encephalitis: properties of the brainassociated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J-Virol. doi
  159. (1997). Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J-Gen-Virol.
  160. (1996). Yellow fever: a decade of reemergence. JAMA. doi
  161. (2001). Yellow fever: an update. Lancet-Infect-Dis. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.